Wegovy and Ozempic contain the exact same active ingredient, semaglutide, and they’re both made by the same company, Novo Nordisk. But they are not interchangeable. The two drugs are approved for different medical purposes, come in different doses, and use different pen designs. Think of them as the same molecule packaged for two distinct jobs.
Same Ingredient, Different Purpose
Semaglutide is a GLP-1 receptor agonist, meaning it mimics a natural gut hormone called GLP-1. This hormone does several things at once: it triggers insulin release when blood sugar is high, slows stomach emptying so you feel full longer, and acts on appetite centers in the brain to reduce hunger. It also shifts how your body handles fat, promoting the breakdown of stored fat while reducing new fat production.
Ozempic is FDA-approved to treat type 2 diabetes. Its primary goal is blood sugar control. In clinical trials, the 1.0 mg weekly dose lowered HbA1c (a measure of average blood sugar over three months) by 1.5% to 1.8% after 30 to 56 weeks. Weight loss happens as a side effect, but it’s not what Ozempic is officially prescribed for.
Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition. In March 2024, the FDA also approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who have obesity or overweight. That cardiovascular approval is unique to Wegovy and does not apply to Ozempic.
The Dosing Is Significantly Different
This is the most important practical difference. Ozempic tops out at 2 mg per week. Wegovy’s standard maintenance dose is 2.4 mg per week, and patients who can’t tolerate that may step down to 1.7 mg. Both drugs use a gradual dose escalation, increasing every four weeks to minimize side effects, but Wegovy’s escalation ladder climbs higher.
That higher ceiling matters for weight loss. In the STEP 1 trial, participants taking semaglutide at 2.4 mg weekly (the Wegovy dose) lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. About 86% of people on the drug lost at least 5% of their body weight. Those results came from the dose that only Wegovy provides.
Different Pen, Different Routine
Both are once-weekly injections you give yourself in the thigh, abdomen, or upper arm. But the devices aren’t the same. Ozempic uses a multi-use pen, meaning a single pen contains multiple doses and you dial the amount each time. Wegovy uses single-use prefilled pens: each pen contains one dose, and you throw it away after a single injection. The Wegovy approach is simpler (no dialing), but it means more pens in the box.
Side Effects Are Similar
Because the active ingredient is the same, the side effect profile overlaps almost entirely. Gastrointestinal issues dominate. In a large real-world analysis of over 10,000 adults using GLP-1 receptor agonists, abdominal pain was the most common complaint at 57.6%, followed by diarrhea (32.7%), constipation (30.4%), and nausea and vomiting (23.4%). Less common but more serious issues included gastroparesis (delayed stomach emptying) at 5.1% and pancreatitis at 3.4%.
These side effects tend to be worst during dose escalation and often improve as your body adjusts. Semaglutide actually had lower rates of certain GI problems compared to older GLP-1 drugs like dulaglutide and liraglutide, which showed higher odds of abdominal pain, nausea, and gastroparesis.
Insurance Coverage Works Differently
Getting insurance to pay for these two drugs can be a very different experience. Ozempic, as a diabetes medication, is covered by most insurance plans when prescribed for type 2 diabetes. The path is relatively straightforward.
Wegovy is a harder sell with insurers. Most plans require prior authorization, meaning your doctor has to submit a form and wait up to 10 business days for approval. Coverage varies widely depending on your plan and what the prescription is for. Medicare and Medicare Part D generally do not cover Wegovy for weight loss alone, though they may cover it when prescribed specifically for cardiovascular risk reduction in eligible patients. Medicaid coverage for weight loss varies by state, with broader access sometimes available for the cardiovascular indication.
This gap in coverage is one reason doctors sometimes prescribe Ozempic off-label for weight loss. It’s the same molecule, and insurance is more likely to cover a diabetes drug. But the maximum Ozempic dose (2 mg) is lower than Wegovy’s maintenance dose (2.4 mg), so the weight loss results may not match what the clinical trials showed for Wegovy.
Can You Switch Between Them?
Because both contain semaglutide, switching is medically straightforward, and your doctor can transition you from one to the other without a new titration period if you’re already on a stable dose. The FDA does note that Wegovy should not be used in combination with other semaglutide-containing products, so you would never take both at the same time. If you’re on Ozempic for diabetes and want to add weight management, the move would be to switch to Wegovy at an equivalent or higher dose, not to stack them.
The limiting factor is usually insurance, not biology. If your plan covers Ozempic for diabetes but won’t approve Wegovy for weight loss, your options narrow. Your doctor can help navigate which drug makes sense given your diagnosis, goals, and coverage.